Envestnet Asset Management Inc. Grows Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Envestnet Asset Management Inc. increased its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 124.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 169,926 shares of the company's stock after purchasing an additional 94,192 shares during the period. Envestnet Asset Management Inc. owned 0.34% of Prestige Consumer Healthcare worth $13,270,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its stake in shares of Prestige Consumer Healthcare by 3.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company's stock worth $126,274,000 after buying an additional 49,331 shares during the period. Geode Capital Management LLC lifted its position in Prestige Consumer Healthcare by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company's stock worth $105,342,000 after acquiring an additional 21,951 shares during the period. Congress Asset Management Co. lifted its position in Prestige Consumer Healthcare by 5.0% during the 4th quarter. Congress Asset Management Co. now owns 908,742 shares of the company's stock worth $70,964,000 after acquiring an additional 43,619 shares during the period. Boston Trust Walden Corp grew its stake in shares of Prestige Consumer Healthcare by 43.5% in the 4th quarter. Boston Trust Walden Corp now owns 831,627 shares of the company's stock valued at $64,942,000 after purchasing an additional 252,089 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Prestige Consumer Healthcare by 5.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company's stock valued at $49,667,000 after purchasing an additional 33,844 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PBH has been the topic of a number of analyst reports. Oppenheimer lifted their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research report on Thursday, February 13th. DA Davidson raised their target price on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Royal Bank of Canada boosted their price target on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a "sector perform" rating in a research note on Friday, March 21st. StockNews.com downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Tuesday, April 8th. Finally, Canaccord Genuity Group lifted their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a report on Friday, February 7th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of "Hold" and a consensus target price of $93.33.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Price Performance

PBH traded up $1.56 on Tuesday, hitting $80.13. 244,415 shares of the company were exchanged, compared to its average volume of 285,548. The business's fifty day moving average is $83.93 and its 200 day moving average is $80.31. Prestige Consumer Healthcare Inc. has a fifty-two week low of $62.35 and a fifty-two week high of $90.04. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The firm has a market capitalization of $3.97 billion, a P/E ratio of 18.77, a price-to-earnings-growth ratio of 2.69 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.